0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Viral Vector and Plasmid DNA Market Research Report 2026
Published Date: 2026-02-26
|
Report Code: QYRE-Auto-23M8886
Home | Market Reports
Global Viral Vector and Plasmid DNA Market Size Status and Forecast 2022
BUY CHAPTERS

Global Viral Vector and Plasmid DNA Market Research Report 2026

Code: QYRE-Auto-23M8886
Report
2026-02-26
Pages:118
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Viral Vector and Plasmid DNA Market Size

The global Viral Vector and Plasmid DNA market was valued at US$ 859 million in 2025 and is anticipated to reach US$ 5325 million by 2032, at a CAGR of 30.2% from 2026 to 2032.

Viral Vector and Plasmid DNA Market

Viral Vector and Plasmid DNA Market

Viral Vector and Plasmid DNA Manufacturing refers to the upstream manufacturing processes essential for gene therapy, cell therapy, mRNA vaccines, and next-generation biologics. It includes the production of high-purity, high-expression plasmid DNA and the preparation of high-titer, functionally stable viral vectors such as adenovirus, lentivirus, and adeno-associated virus (AAV). These processes must be conducted under stringent GMP conditions, often using microbial or mammalian expression systems, and involve key steps such as fermentation, purification, quality control, and encapsulation. With the rapid advancement of biotechnology, this sector is evolving from lab-scale production to industrial-scale manufacturing, becoming a strategic focus for CDMOs and biotech firms worldwide.In this report, we only study the Viral Vector and Plasmid DNA used for research.
As the commercialization of cell and gene therapies accelerates, global demand for viral vectors and plasmid DNA continues to grow. An increasing number of CAR-T therapies, AAV-based gene therapies, and mRNA vaccine programs are advancing into clinical and commercial stages, positioning high-quality vector materials as critical bottleneck resources. Meanwhile, supportive government policies promoting the localization of gene therapy and vaccine production are driving investment in GMP-compliant vector platforms. The expanding CDMO market, stronger outsourcing trends among biotech companies, and process optimization efforts lowering production costs are jointly propelling this sector toward rapid development.
Despite strong demand, the sector faces technical and regulatory hurdles. Standardization remains limited, with cross-platform consistency in production still difficult to achieve. The bar for quality control is high, requiring strict management of viral safety, residual nucleic acids, and encapsulation efficiency. Moreover, premium GMP capacity is still dominated by a few multinational firms, while emerging players often face challenges in infrastructure investment, technical expertise, and talent acquisition. Regulatory scrutiny is also intensifying, lengthening development timelines and raising entry thresholds.
Clinical pipeline expansion and commercial product launches are the primary growth drivers for this field. In indications such as rare diseases, cancer immunotherapy, and neurological disorders, the use of AAV and lentiviral vectors is increasing significantly. At the same time, plasmid DNA is widely used as a starting template or precursor for mRNA, vaccines, nucleic acid drugs, and CRISPR-based therapies. Strategic partnerships between pharma and CDMO players are proliferating to develop modular, scalable manufacturing platforms that can support a diverse array of downstream applications.
This report delivers a comprehensive overview of the global Viral Vector and Plasmid DNA market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Viral Vector and Plasmid DNA. The Viral Vector and Plasmid DNA market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Viral Vector and Plasmid DNA market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Viral Vector and Plasmid DNA manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Viral Vector and Plasmid DNA Market Report

Report Metric Details
Report Name Viral Vector and Plasmid DNA Market
Accounted market size in 2025 US$ 859 million
Forecasted market size in 2032 US$ 5325 million
CAGR 30.2%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • AAV
  • Lentiviruses
  • Retroviruses
  • Adenoviruses
  • DNA Plasmids
  • Other
Segment by Application
  • Pharmaceutical and Biopharmaceutical Companies
  • Academics and Research Institutes
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Thermo Fisher Scientific, Lonza, Azenta Life Sciences, Revvity, VectorBuilder, Takara Bio, GenScript Biotech, Gene Chem, Geno Meditech, PackGene Biotech, VIROVEK, OriGen, Vector BioLabs
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Viral Vector and Plasmid DNA companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Viral Vector and Plasmid DNA Market growing?

Ans: The Viral Vector and Plasmid DNA Market witnessing a CAGR of 30.2% during the forecast period 2026-2032.

What is the Viral Vector and Plasmid DNA Market size in 2032?

Ans: The Viral Vector and Plasmid DNA Market size in 2032 will be US$ 5325 million.

Who are the main players in the Viral Vector and Plasmid DNA Market report?

Ans: The main players in the Viral Vector and Plasmid DNA Market are Thermo Fisher Scientific, Lonza, Azenta Life Sciences, Revvity, VectorBuilder, Takara Bio, GenScript Biotech, Gene Chem, Geno Meditech, PackGene Biotech, VIROVEK, OriGen, Vector BioLabs

What are the Application segmentation covered in the Viral Vector and Plasmid DNA Market report?

Ans: The Applications covered in the Viral Vector and Plasmid DNA Market report are Pharmaceutical and Biopharmaceutical Companies, Academics and Research Institutes

What are the Type segmentation covered in the Viral Vector and Plasmid DNA Market report?

Ans: The Types covered in the Viral Vector and Plasmid DNA Market report are AAV, Lentiviruses, Retroviruses, Adenoviruses, DNA Plasmids, Other

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vector and Plasmid DNA Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 AAV
1.2.3 Lentiviruses
1.2.4 Retroviruses
1.2.5 Adenoviruses
1.2.6 DNA Plasmids
1.2.7 Other
1.3 Market by Application
1.3.1 Global Viral Vector and Plasmid DNA Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Academics and Research Institutes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector and Plasmid DNA Market Perspective (2021–2032)
2.2 Global Viral Vector and Plasmid DNA Growth Trends by Region
2.2.1 Global Viral Vector and Plasmid DNA Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Viral Vector and Plasmid DNA Historic Market Size by Region (2021–2026)
2.2.3 Viral Vector and Plasmid DNA Forecasted Market Size by Region (2027–2032)
2.3 Viral Vector and Plasmid DNA Market Dynamics
2.3.1 Viral Vector and Plasmid DNA Industry Trends
2.3.2 Viral Vector and Plasmid DNA Market Drivers
2.3.3 Viral Vector and Plasmid DNA Market Challenges
2.3.4 Viral Vector and Plasmid DNA Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vector and Plasmid DNA Players by Revenue
3.1.1 Global Top Viral Vector and Plasmid DNA Players by Revenue (2021–2026)
3.1.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Players (2021–2026)
3.2 Global Top Viral Vector and Plasmid DNA Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Viral Vector and Plasmid DNA Revenue
3.4 Global Viral Vector and Plasmid DNA Market Concentration Ratio
3.4.1 Global Viral Vector and Plasmid DNA Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vector and Plasmid DNA Revenue in 2025
3.5 Global Key Players of Viral Vector and Plasmid DNA Head Offices and Areas Served
3.6 Global Key Players of Viral Vector and Plasmid DNA, Products and Applications
3.7 Global Key Players of Viral Vector and Plasmid DNA, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Viral Vector and Plasmid DNA Breakdown Data by Type
4.1 Global Viral Vector and Plasmid DNA Historic Market Size by Type (2021–2026)
4.2 Global Viral Vector and Plasmid DNA Forecasted Market Size by Type (2027–2032)
5 Viral Vector and Plasmid DNA Breakdown Data by Application
5.1 Global Viral Vector and Plasmid DNA Historic Market Size by Application (2021–2026)
5.2 Global Viral Vector and Plasmid DNA Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Viral Vector and Plasmid DNA Market Size (2021–2032)
6.2 North America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Viral Vector and Plasmid DNA Market Size by Country (2021–2026)
6.4 North America Viral Vector and Plasmid DNA Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vector and Plasmid DNA Market Size (2021–2032)
7.2 Europe Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Viral Vector and Plasmid DNA Market Size by Country (2021–2026)
7.4 Europe Viral Vector and Plasmid DNA Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Viral Vector and Plasmid DNA Market Size (2021–2032)
8.2 Asia-Pacific Viral Vector and Plasmid DNA Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Region (2021–2026)
8.4 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Viral Vector and Plasmid DNA Market Size (2021–2032)
9.2 Latin America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Viral Vector and Plasmid DNA Market Size by Country (2021–2026)
9.4 Latin America Viral Vector and Plasmid DNA Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vector and Plasmid DNA Market Size (2021–2032)
10.2 Middle East & Africa Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2021–2026)
10.4 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Viral Vector and Plasmid DNA Introduction
11.1.4 Thermo Fisher Scientific Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Viral Vector and Plasmid DNA Introduction
11.2.4 Lonza Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.2.5 Lonza Recent Development
11.3 Azenta Life Sciences
11.3.1 Azenta Life Sciences Company Details
11.3.2 Azenta Life Sciences Business Overview
11.3.3 Azenta Life Sciences Viral Vector and Plasmid DNA Introduction
11.3.4 Azenta Life Sciences Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.3.5 Azenta Life Sciences Recent Development
11.4 Revvity
11.4.1 Revvity Company Details
11.4.2 Revvity Business Overview
11.4.3 Revvity Viral Vector and Plasmid DNA Introduction
11.4.4 Revvity Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.4.5 Revvity Recent Development
11.5 VectorBuilder
11.5.1 VectorBuilder Company Details
11.5.2 VectorBuilder Business Overview
11.5.3 VectorBuilder Viral Vector and Plasmid DNA Introduction
11.5.4 VectorBuilder Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.5.5 VectorBuilder Recent Development
11.6 Takara Bio
11.6.1 Takara Bio Company Details
11.6.2 Takara Bio Business Overview
11.6.3 Takara Bio Viral Vector and Plasmid DNA Introduction
11.6.4 Takara Bio Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.6.5 Takara Bio Recent Development
11.7 GenScript Biotech
11.7.1 GenScript Biotech Company Details
11.7.2 GenScript Biotech Business Overview
11.7.3 GenScript Biotech Viral Vector and Plasmid DNA Introduction
11.7.4 GenScript Biotech Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.7.5 GenScript Biotech Recent Development
11.8 Gene Chem
11.8.1 Gene Chem Company Details
11.8.2 Gene Chem Business Overview
11.8.3 Gene Chem Viral Vector and Plasmid DNA Introduction
11.8.4 Gene Chem Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.8.5 Gene Chem Recent Development
11.9 Geno Meditech
11.9.1 Geno Meditech Company Details
11.9.2 Geno Meditech Business Overview
11.9.3 Geno Meditech Viral Vector and Plasmid DNA Introduction
11.9.4 Geno Meditech Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.9.5 Geno Meditech Recent Development
11.10 PackGene Biotech
11.10.1 PackGene Biotech Company Details
11.10.2 PackGene Biotech Business Overview
11.10.3 PackGene Biotech Viral Vector and Plasmid DNA Introduction
11.10.4 PackGene Biotech Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.10.5 PackGene Biotech Recent Development
11.11 VIROVEK
11.11.1 VIROVEK Company Details
11.11.2 VIROVEK Business Overview
11.11.3 VIROVEK Viral Vector and Plasmid DNA Introduction
11.11.4 VIROVEK Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.11.5 VIROVEK Recent Development
11.12 OriGen
11.12.1 OriGen Company Details
11.12.2 OriGen Business Overview
11.12.3 OriGen Viral Vector and Plasmid DNA Introduction
11.12.4 OriGen Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.12.5 OriGen Recent Development
11.13 Vector BioLabs
11.13.1 Vector BioLabs Company Details
11.13.2 Vector BioLabs Business Overview
11.13.3 Vector BioLabs Viral Vector and Plasmid DNA Introduction
11.13.4 Vector BioLabs Revenue in Viral Vector and Plasmid DNA Business (2021–2026)
11.13.5 Vector BioLabs Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Viral Vector and Plasmid DNA Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of AAV
 Table 3. Key Players of Lentiviruses
 Table 4. Key Players of Retroviruses
 Table 5. Key Players of Adenoviruses
 Table 6. Key Players of DNA Plasmids
 Table 7. Key Players of Other
 Table 8. Global Viral Vector and Plasmid DNA Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 9. Global Viral Vector and Plasmid DNA Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 10. Global Viral Vector and Plasmid DNA Market Size by Region (US$ Million), 2021–2026
 Table 11. Global Viral Vector and Plasmid DNA Market Share by Region (2021–2026)
 Table 12. Global Viral Vector and Plasmid DNA Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 13. Global Viral Vector and Plasmid DNA Market Share by Region (2027–2032)
 Table 14. Viral Vector and Plasmid DNA Market Trends
 Table 15. Viral Vector and Plasmid DNA Market Drivers
 Table 16. Viral Vector and Plasmid DNA Market Challenges
 Table 17. Viral Vector and Plasmid DNA Market Restraints
 Table 18. Global Viral Vector and Plasmid DNA Revenue by Players (US$ Million), 2021–2026
 Table 19. Global Viral Vector and Plasmid DNA Market Share by Players (2021–2026)
 Table 20. Global Top Viral Vector and Plasmid DNA Players by Tier (Tier 1, Tier 2, and Tier 3), based on Viral Vector and Plasmid DNA Revenue, 2025
 Table 21. Ranking of Global Top Viral Vector and Plasmid DNA Companies by Revenue (US$ Million) in 2025
 Table 22. Global 5 Largest Players Market Share by Viral Vector and Plasmid DNA Revenue (CR5 and HHI), 2021–2026
 Table 23. Global Key Players of Viral Vector and Plasmid DNA, Headquarters and Area Served
 Table 24. Global Key Players of Viral Vector and Plasmid DNA, Products and Applications
 Table 25. Global Key Players of Viral Vector and Plasmid DNA, Date of General Availability (GA)
 Table 26. Mergers and Acquisitions, Expansion Plans
 Table 27. Global Viral Vector and Plasmid DNA Market Size by Type (US$ Million), 2021–2026
 Table 28. Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2021–2026)
 Table 29. Global Viral Vector and Plasmid DNA Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 30. Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2027–2032)
 Table 31. Global Viral Vector and Plasmid DNA Market Size by Application (US$ Million), 2021–2026
 Table 32. Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2021–2026)
 Table 33. Global Viral Vector and Plasmid DNA Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 34. Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2027–2032)
 Table 35. North America Viral Vector and Plasmid DNA Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 36. North America Viral Vector and Plasmid DNA Market Size by Country (US$ Million), 2021–2026
 Table 37. North America Viral Vector and Plasmid DNA Market Size by Country (US$ Million), 2027–2032
 Table 38. Europe Viral Vector and Plasmid DNA Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 39. Europe Viral Vector and Plasmid DNA Market Size by Country (US$ Million), 2021–2026
 Table 40. Europe Viral Vector and Plasmid DNA Market Size by Country (US$ Million), 2027–2032
 Table 41. Asia-Pacific Viral Vector and Plasmid DNA Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 42. Asia-Pacific Viral Vector and Plasmid DNA Market Size by Region (US$ Million), 2021–2026
 Table 43. Asia-Pacific Viral Vector and Plasmid DNA Market Size by Region (US$ Million), 2027–2032
 Table 44. Latin America Viral Vector and Plasmid DNA Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 45. Latin America Viral Vector and Plasmid DNA Market Size by Country (US$ Million), 2021–2026
 Table 46. Latin America Viral Vector and Plasmid DNA Market Size by Country (US$ Million), 2027–2032
 Table 47. Middle East & Africa Viral Vector and Plasmid DNA Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 48. Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (US$ Million), 2021–2026
 Table 49. Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (US$ Million), 2027–2032
 Table 50. Thermo Fisher Scientific Company Details
 Table 51. Thermo Fisher Scientific Business Overview
 Table 52. Thermo Fisher Scientific Viral Vector and Plasmid DNA Product
 Table 53. Thermo Fisher Scientific Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 54. Thermo Fisher Scientific Recent Development
 Table 55. Lonza Company Details
 Table 56. Lonza Business Overview
 Table 57. Lonza Viral Vector and Plasmid DNA Product
 Table 58. Lonza Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 59. Lonza Recent Development
 Table 60. Azenta Life Sciences Company Details
 Table 61. Azenta Life Sciences Business Overview
 Table 62. Azenta Life Sciences Viral Vector and Plasmid DNA Product
 Table 63. Azenta Life Sciences Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 64. Azenta Life Sciences Recent Development
 Table 65. Revvity Company Details
 Table 66. Revvity Business Overview
 Table 67. Revvity Viral Vector and Plasmid DNA Product
 Table 68. Revvity Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 69. Revvity Recent Development
 Table 70. VectorBuilder Company Details
 Table 71. VectorBuilder Business Overview
 Table 72. VectorBuilder Viral Vector and Plasmid DNA Product
 Table 73. VectorBuilder Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 74. VectorBuilder Recent Development
 Table 75. Takara Bio Company Details
 Table 76. Takara Bio Business Overview
 Table 77. Takara Bio Viral Vector and Plasmid DNA Product
 Table 78. Takara Bio Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 79. Takara Bio Recent Development
 Table 80. GenScript Biotech Company Details
 Table 81. GenScript Biotech Business Overview
 Table 82. GenScript Biotech Viral Vector and Plasmid DNA Product
 Table 83. GenScript Biotech Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 84. GenScript Biotech Recent Development
 Table 85. Gene Chem Company Details
 Table 86. Gene Chem Business Overview
 Table 87. Gene Chem Viral Vector and Plasmid DNA Product
 Table 88. Gene Chem Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 89. Gene Chem Recent Development
 Table 90. Geno Meditech Company Details
 Table 91. Geno Meditech Business Overview
 Table 92. Geno Meditech Viral Vector and Plasmid DNA Product
 Table 93. Geno Meditech Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 94. Geno Meditech Recent Development
 Table 95. PackGene Biotech Company Details
 Table 96. PackGene Biotech Business Overview
 Table 97. PackGene Biotech Viral Vector and Plasmid DNA Product
 Table 98. PackGene Biotech Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 99. PackGene Biotech Recent Development
 Table 100. VIROVEK Company Details
 Table 101. VIROVEK Business Overview
 Table 102. VIROVEK Viral Vector and Plasmid DNA Product
 Table 103. VIROVEK Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 104. VIROVEK Recent Development
 Table 105. OriGen Company Details
 Table 106. OriGen Business Overview
 Table 107. OriGen Viral Vector and Plasmid DNA Product
 Table 108. OriGen Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 109. OriGen Recent Development
 Table 110. Vector BioLabs Company Details
 Table 111. Vector BioLabs Business Overview
 Table 112. Vector BioLabs Viral Vector and Plasmid DNA Product
 Table 113. Vector BioLabs Revenue in Viral Vector and Plasmid DNA Business (US$ Million), 2021–2026
 Table 114. Vector BioLabs Recent Development
 Table 115. Research Programs/Design for This Report
 Table 116. Key Data Information from Secondary Sources
 Table 117. Key Data Information from Primary Sources
 Table 118. Authors List of This Report


List of Figures
 Figure 1. Viral Vector and Plasmid DNA Picture
 Figure 2. Global Viral Vector and Plasmid DNA Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Viral Vector and Plasmid DNA Market Share by Type: 2025 vs 2032
 Figure 4. AAV Features
 Figure 5. Lentiviruses Features
 Figure 6. Retroviruses Features
 Figure 7. Adenoviruses Features
 Figure 8. DNA Plasmids Features
 Figure 9. Other Features
 Figure 10. Global Viral Vector and Plasmid DNA Market Size by Application (US$ Million), 2021–2032
 Figure 11. Global Viral Vector and Plasmid DNA Market Share by Application: 2025 vs 2032
 Figure 12. Pharmaceutical and Biopharmaceutical Companies Case Studies
 Figure 13. Academics and Research Institutes Case Studies
 Figure 14. Viral Vector and Plasmid DNA Report Years Considered
 Figure 15. Global Viral Vector and Plasmid DNA Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 16. Global Viral Vector and Plasmid DNA Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 17. Global Viral Vector and Plasmid DNA Market Share by Region: 2025 vs 2032
 Figure 18. Global Viral Vector and Plasmid DNA Market Share by Players in 2025
 Figure 19. Global Viral Vector and Plasmid DNA Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 20. The Top 10 and 5 Players Market Share by Viral Vector and Plasmid DNA Revenue in 2025
 Figure 21. North America Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. North America Viral Vector and Plasmid DNA Market Share by Country (2021–2032)
 Figure 23. United States Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Canada Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. Europe Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. Europe Viral Vector and Plasmid DNA Market Share by Country (2021–2032)
 Figure 27. Germany Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. France Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. U.K. Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Italy Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Russia Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Ireland Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Asia-Pacific Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Asia-Pacific Viral Vector and Plasmid DNA Market Share by Region (2021–2032)
 Figure 35. China Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Japan Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. South Korea Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Southeast Asia Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. India Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Australia & New Zealand Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Latin America Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Latin America Viral Vector and Plasmid DNA Market Share by Country (2021–2032)
 Figure 43. Mexico Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Brazil Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Middle East & Africa Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Middle East & Africa Viral Vector and Plasmid DNA Market Share by Country (2021–2032)
 Figure 47. Israel Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Saudi Arabia Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 49. UAE Viral Vector and Plasmid DNA Market Size YoY Growth (US$ Million), 2021–2032
 Figure 50. Thermo Fisher Scientific Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 51. Lonza Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 52. Azenta Life Sciences Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 53. Revvity Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 54. VectorBuilder Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 55. Takara Bio Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 56. GenScript Biotech Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 57. Gene Chem Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 58. Geno Meditech Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 59. PackGene Biotech Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 60. VIROVEK Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 61. OriGen Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 62. Vector BioLabs Revenue Growth Rate in Viral Vector and Plasmid DNA Business (2021–2026)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS